ET 104 (zonisamide oral suspension) is filed at the FDA to treat partial seizures in patients with epilepsy.- Eton Pharma

Eton Pharmaceuticals, Inc a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has submitted a new drug application (NDA) for zonisamide oral suspension, previously known as the company’s ET 104 product candidate, to the FDA for the treatment of partial seizures in patients with epilepsy. Zonisamide is widely used as a capsule to treat partial seizures, but the molecule is not FDA approved in liquid form. Eton’s patent-pending liquid formulation addresses the significant unmet need for patients with dysphagia and patients that require the precision dosing that a liquid product offers. Based on IQVIA data, more than 150,000 prescriptions of zonisamide are written annually for the treatment of epilepsy.